Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1992 Nov;66(11):6714–6720. doi: 10.1128/jvi.66.11.6714-6720.1992

A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus.

S C Cheung 1, B Dietzschold 1, H Koprowski 1, A L Notkins 1, R F Rando 1
PMCID: PMC240167  PMID: 1404611

Abstract

A recombinant human anti-rabies monoclonal antibody (MAb-57) Fab was prepared by cloning the heavy (Fd)- and light-chain domains into the same bacterial expression vector. To construct the recombinant Fab, mRNA was extracted from MAb-57-producing hybridoma cells, reverse transcribed, and then amplified by polymerase chain reaction (PCR) by using oligonucleotides specific for immunoglobulin heavy- and light-chain DNA sequences. PCR-amplified Fd-chain cDNA was fused, in frame, between a bacterial leader peptide (PelB) at the amino terminus and a 10-amino-acid peptide tag at the carboxy terminus. The PCR-amplified lambda-chain cDNA was also fused to the PelB leader peptide. The immunoglobulin Fab was then expressed as a dicistronic message in bacteria by using the isopropyl-beta-D-thiogalactopyranoside-inducible lactose promotor (lacZ). DNA sequencing was used to define the gamma-chain isotype (immunoglobulin G1) and VH (VHI) chain and VL (V lambda II) chain gene usage. The recombinant Fab (rFab57) specifically bound the rabies virus coat glycoprotein, while the Fd and lambda chains, when expressed individually, did not. The binding specificity of rFab57 was indistinguishable from that of the intact MAb in direct enzyme-linked immunosorbent assays; however, the dissociation constant of rFab57 for rabies virus protein G was approximately 1 log10 U lower than that of complete MAb-57 in competition enzyme-linked immunosorbent assays. A fluorescent-focus inhibition assay showed that bacterially expressed rFab was capable of neutralizing rabies virus strain CVS-11. We conclude that a human Fab expressed in bacteria maintains its specificity and biologic activity.

Full text

PDF
6714

Images in this article

6718Image
on p.6718

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashe W. K., Mage M., Mage R., Notkins A. L. Neutralization and sensitization of herpes simplex virus with antibody fragments from rabbits of different allotypes. J Immunol. 1968 Sep;101(3):500–504. [PubMed] [Google Scholar]
  2. BALTAZARD M., BAHMANYAR M. Essai pratique du sérum antirabique chez les mordus par loups enragés. Bull World Health Organ. 1955;13(5):747–772. [PMC free article] [PubMed] [Google Scholar]
  3. Better M., Chang C. P., Robinson R. R., Horwitz A. H. Escherichia coli secretion of an active chimeric antibody fragment. Science. 1988 May 20;240(4855):1041–1043. doi: 10.1126/science.3285471. [DOI] [PubMed] [Google Scholar]
  4. Buchegger F., Mach J. P., Leonnard P., Carrel S. Selective tumor localization of radiolabeled anti-human melanoma monoclonal antibody fragment demonstrated in the nude mouse model. Cancer. 1986 Aug 1;58(3):655–662. doi: 10.1002/1097-0142(19860801)58:3<655::aid-cncr2820580310>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  5. Bögel K., Motschwiller E. Incidence of rabies and post-exposure treatment in developing countries. Bull World Health Organ. 1986;64(6):883–887. [PMC free article] [PubMed] [Google Scholar]
  6. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  7. Colonno R. J., Callahan P. L., Leippe D. M., Rueckert R. R., Tomassini J. E. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol. 1989 Jan;63(1):36–42. doi: 10.1128/jvi.63.1.36-42.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cremer N. E., Riggs J. L., Lennette E. H. Neutralization kinetics of western equine encephalitis virus by antibody fragments. Immunochemistry. 1975 Jul;12(6-7):597–601. doi: 10.1016/0019-2791(75)90092-0. [DOI] [PubMed] [Google Scholar]
  9. Dietzschold B., Cox J. H., Schneider L. G., Wiktor T. J., Koprowski H. Isolation and purification of a polymeric form of the glycoprotein of rabies virus. J Gen Virol. 1978 Jul;40(1):131–139. doi: 10.1099/0022-1317-40-1-131. [DOI] [PubMed] [Google Scholar]
  10. Dietzschold B., Gore M., Casali P., Ueki Y., Rupprecht C. E., Notkins A. L., Koprowski H. Biological characterization of human monoclonal antibodies to rabies virus. J Virol. 1990 Jun;64(6):3087–3090. doi: 10.1128/jvi.64.6.3087-3090.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ellison J. W., Berson B. J., Hood L. E. The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071–4079. doi: 10.1093/nar/10.13.4071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Enssle K., Kurrle R., Köhler R., Müller H., Kanzy E. J., Hilfenhaus J., Seiler F. R. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma. 1991 Oct;10(5):547–556. doi: 10.1089/hyb.1991.10.547. [DOI] [PubMed] [Google Scholar]
  13. Friguet B., Chaffotte A. F., Djavadi-Ohaniance L., Goldberg M. E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985 Mar 18;77(2):305–319. doi: 10.1016/0022-1759(85)90044-4. [DOI] [PubMed] [Google Scholar]
  14. Gebauer W., Lindl T. Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation. Arzneimittelforschung. 1990 Jun;40(6):718–722. [PubMed] [Google Scholar]
  15. Glockshuber R., Stadlmüller J., Plückthun A. Mapping and modification of an antibody hapten binding site: a site-directed mutagenesis study of McPC603. Biochemistry. 1991 Mar 26;30(12):3049–3054. doi: 10.1021/bi00226a010. [DOI] [PubMed] [Google Scholar]
  16. Hasemann C. A., Capra J. D. High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. Proc Natl Acad Sci U S A. 1990 May;87(10):3942–3946. doi: 10.1073/pnas.87.10.3942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Huse W. D., Sastry L., Iverson S. A., Kang A. S., Alting-Mees M., Burton D. R., Benkovic S. J., Lerner R. A. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989 Dec 8;246(4935):1275–1281. doi: 10.1126/science.2531466. [DOI] [PubMed] [Google Scholar]
  18. KOPROWSKI H., VAN DER SCHEER J., BLACK J. Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med. 1950 Apr;8(4):412–420. doi: 10.1016/0002-9343(50)90224-5. [DOI] [PubMed] [Google Scholar]
  19. Kingsford L., Boucquey K. H., Cardoso T. P. Effects of specific monoclonal antibodies on La Crosse virus neutralization: aggregation, inactivation by Fab fragments, and inhibition of attachment to baby hamster kidney cells. Virology. 1991 Feb;180(2):591–601. doi: 10.1016/0042-6822(91)90073-k. [DOI] [PubMed] [Google Scholar]
  20. Kipps T. J., Duffy S. F. Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. J Clin Invest. 1991 Jun;87(6):2087–2096. doi: 10.1172/JCI115239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lafon M., Edelman L., Bouvet J. P., Lafage M., Montchâtre E. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol. 1990 Aug;71(Pt 8):1689–1696. doi: 10.1099/0022-1317-71-8-1689. [DOI] [PubMed] [Google Scholar]
  22. Libeau G., Lafon M. Production of monoclonal antibodies against the Pasteur (P.V.) strain of rabies virus: problems and results. Dev Biol Stand. 1984;57:213–218. [PubMed] [Google Scholar]
  23. Mach J. P., Chatal J. F., Lumbroso J. D., Buchegger F., Forni M., Ritschard J., Berche C., Douillard J. Y., Carrel S., Herlyn M. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res. 1983 Nov;43(11):5593–5600. [PubMed] [Google Scholar]
  24. Mathews J. H., Roehrig J. T., Trent D. W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol. 1985 Sep;55(3):594–600. doi: 10.1128/jvi.55.3.594-600.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mueller B. M., Reisfeld R. A., Gillies S. D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5702–5705. doi: 10.1073/pnas.87.15.5702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pearson W. R., Lipman D. J. Improved tools for biological sequence comparison. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444–2448. doi: 10.1073/pnas.85.8.2444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Plückthun A. Antibody engineering: advances from the use of Escherichia coli expression systems. Biotechnology (N Y) 1991 Jun;9(6):545–551. doi: 10.1038/nbt0691-545. [DOI] [PubMed] [Google Scholar]
  28. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sikes R. K., Cleary W. F., Koprowski H., Wiktor T. J., Kaplan M. M. Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ. 1971;45(1):1–11. [PMC free article] [PubMed] [Google Scholar]
  30. Sissons J. G., Cooper N. R., Oldstone M. B. Alternative complement pathway-mediated lysis of measles virus infected cells: induction by IgG antibody bound to individual viral glycoproteins and comparative efficacy of F(ab')2 and Fab' fragments. J Immunol. 1979 Nov;123(5):2144–2149. [PubMed] [Google Scholar]
  31. Ueki Y., Goldfarb I. S., Harindranath N., Gore M., Koprowski H., Notkins A. L., Casali P. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med. 1990 Jan 1;171(1):19–34. doi: 10.1084/jem.171.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vasicek T. J., Leder P. Structure and expression of the human immunoglobulin lambda genes. J Exp Med. 1990 Aug 1;172(2):609–620. doi: 10.1084/jem.172.2.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wiktor T. J., Dietzschold B., Leamnson R. N., Koprowski H. Induction and biological properties of defective interfering particles of rabies virus. J Virol. 1977 Feb;21(2):626–635. doi: 10.1128/jvi.21.2.626-635.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wiktor T. J., Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3938–3942. doi: 10.1073/pnas.75.8.3938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wiktor T. J., Macfarlan R. I., Foggin C. M., Koprowski H. Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand. 1984;57:199–211. [PubMed] [Google Scholar]
  36. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. Adverse effects of equine rabies immune gobulin. Vaccine. 1989 Feb;7(1):10–11. doi: 10.1016/0264-410x(89)90003-0. [DOI] [PubMed] [Google Scholar]
  37. Williamson R. A., Persson M. A., Burton D. R. Expression of a human monoclonal anti-(rhesus D) Fab fragment in Escherichia coli with the use of bacteriophage lambda vectors. Biochem J. 1991 Jul 15;277(Pt 2):561–563. doi: 10.1042/bj2770561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wilson I. A., Niman H. L., Houghten R. A., Cherenson A. R., Connolly M. L., Lerner R. A. The structure of an antigenic determinant in a protein. Cell. 1984 Jul;37(3):767–778. doi: 10.1016/0092-8674(84)90412-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES